Potential New Treatment for Advanced Heart Failure
Houston, TX – A patient suffering from advanced heart failure is the first in Texas to be treated with the new investigational drug MYDICAR® in a clinical trial at St. Luke’s Episcopal Hospital, home of the Texas Heart® Institute.
The procedure, involving a catheter-based infusion into the arteries of the heart with an investigational new drug called MYDICAR, was performed in mid-March by Andrew Civitello, MD and Leo Simpson, MD. Dr. Civitello is an interventional cardiologist and heart failure specialist, who serves as the Medical Director of the Heart Transplant Program at St. Luke’s and is the lead investigator on the research project. Reynolds Delgado, MD, Michele Sartori, MD and Scott R. Sherron, MD are also interventional cardiologists and sub-investigators on this research study.
MYDICAR is a genetically targeted enzyme replacement therapy for advanced heart failure. The aim of MYDICAR treatment is to reduce the frequency of hospitalizations and improve many symptoms associated with heart failure by restoring levels of an enzyme known to play a key role in the progression of heart failure. Candidates for MYDICAR are advanced heart failure patients who continue to deteriorate from their disease despite optimal drug therapy, including those who are eligible for either a mechanical support device or a heart transplant.
According to Dr. Civitello, this international, multi-center research trial is randomized, meaning some patients will receive MYDICAR while others will receive a placebo in order to study the safety and efficacy of the investigational drug. Approximately 200 patients in the U.S. and Europe will be participating in the study at approximately 50 locations worldwide, including St. Luke’s in the Texas Medical Center. Continue>
Page | 1 2
Posted in: Pharma | July 22, 2015
Posted in: Pharma | September 24, 2013
Posted in: Pharma | December 3, 2014